Skip Navigation



QJM Advance Access published online on February 27, 2006
QJM, doi:10.1093/qjmed/hcl033
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
99/5/341    most recent
hcl033v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by McCabe, C.
Right arrow Articles by Raftery, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McCabe, C.
Right arrow Articles by Raftery, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: Journals.permissions@oxfordjournals.org

Commentary

Orphan drugs revisited

C. McCabe 1 *, A. Tsuchiya 2, K. Claxton 3, and J. Raftery 4

1 From the Section of Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, UK
2 From the Section of Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, UK; From the Department of Economics, University of Sheffield, Sheffield, UK
3 From the Department of Economics and Related Studies, University of York, York, UK
4 From the Wessex Institute for Health Research and Development, University of Southampton, Southampton, UK

* To whom correspondence should be addressed.
C. McCabe, E-mail: c.mccabe{at}sheffield.ac.uk



This article has no Abstract.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Med. EthicsHome page
M Schlander
The use of cost-effectiveness by the National Institute for Health and Clinical Excellence (NICE): no(t yet an) exemplar of a deliberative process
J. Med. Ethics, July 1, 2008; 34(7): 534 - 539.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.